Why the study?
Cardio-oncology addresses cardiovascular complications associated with cancer therapies, including those linked to the anti-angiogenic agent bevacizumab.
Careful cardiovascular risk assessment and management is essential in patients receiving the anti-angiogenic agent bevacizumab.
Supports cardio-oncology monitoring with bevacizumab; leaves optimal protocols open pending prospective trials.
Cardio-oncology has emerged as a critical multidisciplinary field addressing cardiovascular complications associated with cancer therapies. Bevacizumab, a widely used anti-angiogenic agent targetin...
No takes yet. Share an insight, caveat, or question.
Bourgeois et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: